A new partnership to improve TB treatments around the world

 

endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • a clinical trial
  • advocacy at national and global levels.

Covering 17 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partner UNITAID.

Watch the two-minute animation

 

You can contact us, or follow us on Twitter.

The Lancet: new safety and efficacy findings

Patient holding his medication, he takes up to 26 pills a day to treat XDR-TB. Here he holds his morning selection, which includes delamanid, one of the newest DR-TB drugs, which he is taking for the first time today.

 

14 February 2017

An MSF study on the combined use of new TB drugs in Armenia, India and South Africa shows promising results.

Read more

endTB at the Union Conference

Thumbnail

 

10 October 2017

Attending the UNION conference in Guadalajara (Mexico) on 11-14 October? Don’t miss these events from endTB and partners.

Read more

PIH MSF MSF UNITAID